• Jonathan Chrispin, Seth S Martin, Rani K Hasan, Parag H Joshi, C Michael Minder, John W McEvoy, Payal Kohli, Amber E Johnson, Libin Wang, Michael J Blaha, and Roger S Blumenthal.
• The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins School of Medicine, Baltimore, Maryland.
• Clin Cardiol. 2013 Sep 1; 36 (9): 516-23.

AbstractAlthough atherosclerotic cardiovascular disease (CVD) is the most common cause of morbidity and mortality in the world, the long disease latency affords ample opportunity for preventive care. Indeed, lifelong exposure to atherogenic apoliprotein B-containing lipoproteins has consistently been shown to increase the cumulative risk of suffering a CVD event, including myocardial infarction, stroke, and symptomatic peripheral arterial disease. Over the past 25 years, lipid-lowering therapies have been developed that are proven to not only lower cholesterol, but also to decrease adverse CVD events and CVD mortality. This review will highlight several key clinical trials encompassing several classes of lipid-lowering medications that have provided clinicians with an evidence-based framework for managing their patients' cardiovascular risk. © 2013 Wiley Periodicals, Inc.

10 keywords...

hide…